
GLOW is a multi-peptide complex combining GHK-Cu, BPC-157 and TB-500 — a blend widely used in skin, connective tissue and recovery research. One kit supplies a full protocol from a single verified batch.
| Purity | ≥99% (LC-MS verified) |
| Form | Lyophilized powder, preservative free |
| Storage | Cool and dry; refrigerate after reconstitution |
| Batch | COA available on request |
GLOW is a multi-peptide complex combining GHK-Cu, BPC-157 and TB-500 — a blend widely used in skin, connective tissue and recovery research. One kit supplies a full protocol from a single verified batch.
GLOW is a multi-peptide preparation combining GHK-Cu, BPC-157 and TB-500 in a single lyophilized vial. The three are studied in overlapping connective-tissue and skin research contexts but act through unrelated described mechanisms, which is the rationale for supplying them together.
GHK-Cu contributes copper-binding and matrix-related activity; BPC-157 is associated with angiogenic and nitric-oxide signalling; TB-500 with actin regulation and cell migration. The stated milligram figure is combined content.
Supplied for laboratory research use only. Not for human consumption.
Each component has a separate published mechanism, so a combined preparation allows researchers to observe the three in parallel without handling three vials. Studies of the individual peptides substantially outnumber studies of any combination.
A copper-binding tripeptide associated with extracellular matrix remodelling, collagen synthesis in fibroblast culture, and broad shifts in gene expression.
Associated with VEGFR2 upregulation and nitric-oxide synthase modulation in tissue-repair models.
Reproduces the actin-binding region of thymosin beta-4; associated with migration of endothelial cells, keratinocytes and fibroblasts.
Published research on this specific three-peptide combination is limited. The citations below concern the individual components. None is an approved drug.
Concentration is set by the volume of diluent added. For a 70mg vial, 5mL of bacteriostatic water yields 14mg/mL. Calculate the working concentration your protocol requires rather than following a generic figure.
| State | Temperature | Practical shelf life |
|---|---|---|
| Lyophilized, sealed | −20 °C | 24+ months |
| Lyophilized, sealed | 2–8 °C | ~12 months |
| Lyophilized, sealed | Room temperature | Weeks — transit only |
| Reconstituted, bacteriostatic water | 2–8 °C | ~3–4 weeks |
| Reconstituted, sterile water | 2–8 °C | Same session |
Lyophilized peptide is stable enough to survive shipping at ambient temperature, which is why cold-chain courier service is not required for transit. Long-term storage is a different matter — material intended to be held for months belongs in a freezer.
Protect from light, and avoid repeated freeze-thaw cycles. Each cycle causes measurable degradation, so dividing a reconstituted stock into single-use aliquots before freezing is preferable to thawing and refreezing one vial repeatedly.
Every lot is tested by an independent laboratory using two orthogonal methods. HPLC (high-performance liquid chromatography) establishes purity as a percentage of total peptide content, separating the target compound from truncated sequences and synthesis by-products. LC-MS (liquid chromatography–mass spectrometry) confirms molecular identity by mass.
Both matter. Purity alone is insufficient — a 99% pure sample of the wrong compound is still the wrong compound. Together the two tests establish identity and quality, which is why GLOW is released only after both pass.
The certificate of analysis references the lot number printed on your vial label. Request the COA for your lot at sales@pepsdepot.com.
Peer-reviewed studies indexed in PubMed. Each links to the abstract and, where a free copy exists, to the full text. We link primary sources rather than summarising them second-hand.
Compounds studied alongside this one, or acting through related pathways.
Join the Peps Depot mailing list for high-demand restock alerts, subscriber-only offers, release updates and priority access — plus The Friday Brief, our weekly peptide research newsletter covering what actually moved that week. New compounds, new trial data, regulatory shifts.